Phase 1 Lung Cancer Trial, Not Yet Recruiting NCT07063407 Sponsor: Shanghai Hansoh Biomedical Co., Ltd Condition: Lung Cancer
Back to Lung Cancer

Phase 1 Lung Cancer Trial, Not Yet Recruiting

NCT07063407
Not Yet Recruiting Phase 1

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • Adults aged 18 years or older.
  • People who have been formally diagnosed with extensive-stage small cell lung cancer (a type of lung cancer that has spread).
  • People whose cancer has not gotten worse after completing a standard first-line treatment combination involving platinum-based chemotherapy, etoposide, and an immune checkpoint inhibitor.
  • People with a good general level of physical functioning, able to carry out daily activities with little or no limitation (confirm with trial site).
  • People with an estimated life expectancy of more than 12 weeks.
  • People with adequate bone marrow function and no serious organ problems (confirm with trial site).
  • Women of reproductive age who agree to use effective contraception during the trial and for 6 months after the last dose, and who are not breastfeeding; men must also agree to use effective contraception during the same period.
  • Women must have evidence confirming they are not able to become pregnant (confirm with trial site).
  • People who have read, signed, and dated the informed consent form agreeing to participate.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People with uncontrolled fluid build-up around the lungs, abdomen, or heart.
  • People with known cancer spread to the brain or spinal cord that has not been treated, or that is currently active.
  • People with active autoimmune diseases or active infections.
  • People known to have interstitial lung disease or inflammation of the lungs caused by immune treatments.
  • People with a history of severe allergic reactions, serious reactions to blood transfusions, or known allergy to any ingredient in the study drug HS-20093.
  • People who, in the trial doctor's judgement, are unlikely to follow the study procedures, rules, or requirements.
  • People for whom, in the trial doctor's judgement, safety cannot be assured or whose participation may interfere with study assessments.
  • Women who are pregnant, breastfeeding, or planning to become pregnant during the study.
  • People with a history of nerve damage or mental health conditions, including epilepsy or dementia.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 2 July 2026

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Phase 1
Sponsor
Shanghai Hansoh Biomedical Co., Ltd
Registry
ClinicalTrials.gov
Start date
31 July 2025
Est. completion
30 April 2026

This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.

Primary endpoints

Pogression-free survival (PFS) determined by investigators according to RECIST 1.1

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 2 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov